Generic Nevanac Availability

Nevanac is a brand name of nepafenac ophthalmic, approved by the FDA in the following formulation(s):

NEVANAC (nepafenac - suspension/drops; ophthalmic)

  • Manufacturer: ALCON PHARMS LTD
    Approval date: August 19, 2005
    Strength(s): 0.1% [RLD]

Has a generic version of Nevanac been approved?

No. There is currently no therapeutically equivalent version of Nevanac available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nevanac. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
    Patent 5,475,034
    Issued: December 12, 1995
    Inventor(s): Yanni; John M. & Graff; Gustav & Hellberg; Mark R.
    Assignee(s): Alcon Laboratories, Inc.
    Novel ester and amide derivatives of 3-benzoylphenylacetic acid are disclosed. The use of these novel derivatives and certain known derivatives in topically administrable compositions for the treatment of ophthalmic inflammatory disorders is also disclosed.
    Patent expiration dates:
    • June 6, 2014
      ✓ 
      Patent use: METHOD OF TREATING OCULAR INFLAMMATION
  • Topical nepafenac formulations
    Patent 7,834,059
    Issued: November 16, 2010
    Inventor(s): Wong; Warren
    Assignee(s): Alcon, Inc.
    Topical suspension compositions of nepafenac are disclosed. The compositions are especially suitable for topical ophthalmic administration.
    Patent expiration dates:
    • January 31, 2027
      ✓ 
      Patent use: METHOD OF TREATING OCULAR INFLAMMATION
  • Topical nepafenac formulations
    Patent 8,071,648
    Issued: December 6, 2011
    Inventor(s): Wong; Warren
    Assignee(s): Novartis AG
    Topical suspension compositions of nepafenac are disclosed. The compositions are especially suitable for topical ophthalmic administration.
    Patent expiration dates:
    • December 2, 2025
      ✓ 
      Drug product
  • Topical nepafenac formulations
    Patent 8,324,281
    Issued: December 4, 2012
    Inventor(s): Wong; Warren
    Assignee(s): Novartis AG
    Topical suspension compositions of nepafenac are disclosed. The compositions are especially suitable for topical ophthalmic administration.
    Patent expiration dates:
    • December 2, 2025
      ✓ 
      Drug product

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Advertisement
Close

Recommended

(web4)